Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 sebelipase alfa study in lysosomal acid lipase deficiency
NL-OMON43955Phase 2Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD) and Wolman disease, sponsored by Alexion Pharmaceuticals. Started Jun 2015; status: active, not recruiting.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)Wolman disease
Beyond the preview
Go deeper on NL-OMON43955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43955.